Parvovirus B19 and the pathogenesis of anaemia

Reviews in Medical Virology

Volumn 13, Issue 6, 2003, Pages 347-359

  Chisaka, Hiroshi ^a   Morita, Eiji ^a   Yaegashi, Nobuo ^a   Sugamura, Kazuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN NS1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANEMIA; APLASTIC ANEMIA; APOPTOSIS; BONE MARROW DEPRESSION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL LINEAGE; CHRONIC DISEASE; CLINICAL FEATURE; CYTOTOXICITY; ERYTHROCYTE LIFESPAN; ERYTHROID CELL; HALF LIFE TIME; HEMATOPOIETIC SYSTEM; HUMAN; IMMUNE RESPONSE; INTRAUTERINE INFECTION; MITOSIS INHIBITION; NONHUMAN; PARVOVIRUS; PROTEIN EXPRESSION; REVIEW; SECOND TRIMESTER PREGNANCY; TARGET CELL; TRANSIENT APLASTIC CRISIS; VIRUS EXCRETION; VIRUS INFECTIVITY; VIRUS PATHOGENESIS;

ADULT; ANEMIA; APOPTOSIS; BONE MARROW; CELL CYCLE; CHILD; ERYTHROID PROGENITOR CELLS; ERYTHROPOIESIS; FEMALE; HUMANS; INFANT; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREGNANCY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0242526939     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.395     Document Type: Review

References (88)

1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; I: 72-73.
2. Lukashov VV, Goudsmit J. Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvovirus and links between adeno-associated and avian parvoviruses. J Virol 2001; 75: 2729-2740.
3. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen; Cellular receptor for B19 parvovirus. Science 1993; 262: 114-117.
4. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330: 1192-1196.
5. Brown KE, Young NS, Liu JM. Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol 1994; 16: 1-31.
6. Ozawa K, Young N. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol 1987; 61: 2627-2630.
7. Rosenfeld SJ, Yoshimoto K, Kajigaya S, et al. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest 1992 89: 2023-2029.
8. Ozawa K, Ayub J, Kajigaya S, et al. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988; 62: 2884-2889.
9. Doerig C, Hirt B, Antonietti JP, et al. Nonstructural protein of parvoviruses B19 and minute virus of mice controls transcription. J Virol 1990 64: 387-396.
10. Ozawa K, Ayub J, Kajigaya S, et al. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988 62: 2884-2889.
11. Momoeda M, Wong S, Kawase M, et al. A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J Virol 1994; 68: 8443-8446.
12. Moffat S, Yaegashi N, Tada K, et al. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 74: 3018-3028.
13. 2 phase with accumulation of mitotic cyclins. J Virol 2001; 75: 7555-7563.
14. Morita E, Nakashima A, Asao H, et al. Human parvovirus B19 nonstructural protein (NS1) induces cell cycle arrest at G1 phase. J Virol 2003; 77: 2915-2921.
15. Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated antihemophilia concentrates. Lancet 1994; 343: 211-212.
16. Santagostino E, Mannucci PM, Gringeri A, et al. Eliminating parvovirus B19 from blood products. Lancet 1994; 343: 798-799.
17. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72: 1-10.
18. Saldanha L, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93: 714-719.
19. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152: 257-265.
20. Brown KE, Young NS. Parvoviruses B19 in human disease. Annu Rev Med 1997; 48: 59-67.
21. Brown KE, Young NS. Parvovirus B19 infection and hematopoiesis. Blood Rev 1995; 9: 176-182.
22. Brown KE, Green SW, Antunez de Mayolo J, et al. Congenital anaemia after transplacental B19 parvovirus infection. Lancet 1994; 343: 895-896.
23. Brown T, Anand A, Ritchie LD, et al. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984 2: 1033-1034.
24. Yaegashi N, Niinuma T, Chisaka H, et al. Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo. J Infect 1999; 39: 68-76.
25. Kelleher JF, Luban NL, Mortimer PP, et al. Human serum 'parvovirus': a specific cause of aplastic crisis in children with hereditary spherocytosis. J Pediatr 1983; 102: 720-722.
26. Levy R, Weissman A, Blomberg G, et al. Infection by parvovirus B19 during pregnancy: a review. Obstet Gynecol Survey 1997; 52: 254-259.
27. Potter CG, Potter AC, Hatton CS, et al. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Invest 1987; 79: 1486-1492.
28. Landsteiner K, Levine P. Further observations on individual differences of human blood. Proc Soc Exp Biol Med 1927; 24: 941-942.
29. Marcus DM, Kunda SK, Suzuki A. The P blood group system: recent progress in immunochemistry and genetics. Semin Hematol 1981; 18: 63-71.
30. Naiki M, Fong J, Ledeen R, et al. Structure of the human erythrocyte blood group P1 glycosphingolipid. Biochemistry 1975 14: 4831-4837.
31. Cooling LL, Zhang DS, Walker KE, et al. Detection in human blood platelets of sialyl Lewis X gangliosides, potential ligands for CD62 and other selectins. Glycobiology 1995; 5: 571-581.
32. Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 2001; 75: 4110-4116.
33. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5: 1052-1056.
34. Summerford C, Bartlett JS, Samulski RH. AlphaV-beta5 integrin: a c0-receptor for adeno-associated virus type 2 infection. Nat Med 1992; 5: 78-82.
35. Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol 2000; 111: 1010-1022.
36. Young NS, Abkowitz JL, Luzzatto L. New insights into the pathophysiology of acquired cytopenias. Hematology (Am Soc Hematol Educ Program) 2000; 18-38.
37. Searle K, Schalasta G, Enders G. Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: implications for pathogenesis doubtful. J Med Virol 1998; 56: 192-198.
38. Young N, Harrison M, Moore J, et al. Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro. J Clin Invest 1984; 74: 2024-2032.
39. Broliden K, Tolfvenstam T, Ohlsson S, et al. Persistent B19 parvovirus infection in pediatric malignancies. Med Pediatr Oncol 1998; 31: 66-72.
40. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113: 926-933.
41. Gottlieb F, Deutsch J. Red cell aplasia responsive to immunoglobulin therapy as initial manifestation of human immunodeficiency virus infection. Am J Med 1992; 92: 331-333.
42. Abkowitz JL, Brown KE, Wood RW, et al. Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis 1997; 176: 269-273.
43. Frickhofen N, Chen ZJ, Young NS, et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87: 818-824.
44. Mortimer PP, Humphries RK, Moore JG, et al. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 1983; 302: 426-429.
45. Corcoran A, Doyel S, Waldron D, et al. Impaired gamma interferon responses against parvovirus B19 by recently infected children. J Virol 2000; 74: 9903-9910.
46. Frickhofen N, Young NS. Persistent parvovirus B19 infections in humans. Microb Pathog 1989; 7: 319-327.
47. Kurtzman GJ, Cohen BJ, Field AM, et al. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989; 84: 1114-1123.
48. Bertoni E, Rosati A, Zanazzi M, et al. Severe aplastic anemia due to B19 parvovirus infection in renal transplant recipient. Nephrol Dial Transplant 1995; 10: 1462-1463.
49. Uemura N, Ozawa K, Tani K, et al. Pure red cell aplasia caused by parvovirus B19 infection in a renal transplant recipient. Eur J Haematol 1995; 54: 68-69.
50. Sturm I, Watschinger B, Geissler K, et al. Chronic parvovirus B19 infection-associated pure red cell anaemia in a kidney transplant recipient. Nephrol Dial Tranplant 1996; 11: 1367-1370.
51. Lundqvist A, Tolfvenstam T, Brytting M, et al. Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J Infect Dis 1999; 31: 119-122.
52. Coulombel L, Morinet F, Mielot F. Parvovirus infection, leukemia and immunodeficiency. Lancet 1989; I: 101-102.
53. Pillay D, Patou G, Griffiths P, et al. Secondary parvovirus B19 infection in an immunocompromised child. Pediatr Infect Dis J 1991; 10: 623-624.
54. Moreux N, Ranchin B, Calvet A, et al. Chronic parvovirus B19 infection in a pediatric lung transplanted patient. Transplantation 2002; 73: 565-568.
55. Wong TY, Chan PK, Leung CB, et al. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis 1999; 34: 1132-1136.
56. Ramage JK, Hale A, Gane E, et al. Parvovirus B19-induced red cell aplasia treated with plasmapheresis and immunoglobulin. Lancet 1994; 343: 667-668.
57. Geetha D, Zachary JB, Baldado HM, et al. Pure red cell aplasia caused by parvovirus B19 infection in solid organ transplant recipients; a case report and review of literature. Clin Transplant 2000; 14: 586-591.
58. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998; 105: 174-178.
59. Yaegashi N, Niinuma T, Chisaka H, et al. The incidence of and factors leading to parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect 1998; 37: 28-35.
60. Rouger P, Gane P, Salmon C. Tissue distribution of H, Lewis and P antigens as shown by a panel of 18 monoclonal antibodies. Rev Fr Transfus Immunohematol 1987; 30: 699-708.
61. Lambot MA, Noël JC, Peny MO, et al. Fetal parvovirus B19 infection associated with myocardial necrosis. Prenat Diag 1999; 19: 389-390.
62. Porter HJ, Quantrill AM, Fleming KA. B19 parvovirus infection of myocardial cells. Lancet 1988; I: 535-536.
63. Morey AL, Fleming KA. Immunophenotyping of fetal haemopoietic cells permissive for human parvovirus B19 replication in vitro. Br J Haematol 1992; 82: 302-309.
64. Naides SJ, Weiner CP. Antenatal diagnosis and palliative treatment of non-immune hydrops fetalis secondary to fetal parvovirus B19 infection. Prenat Diag 1989; 9: 105-114.
65. Yaegashi N, Shiraishi H, Takeshita T, et al. Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J Virol 1989; 63: 2422-2426.
66. Chisaka H, Morita E, Murata K, et al. A transgenic mouse model for non-immune hydrops fetalis induced by the NS1 gene parvovirus B19. J Gen Virol 2002; 83: 273-281.
67. Diamond LK, Blackfan KD. Hypoplastic anemia. Am J Dis Child 1938; 46: 441-467.
68. Ball SE, McGuckin CP, Jenkins G, et al. Diamond-Blackfan anemia in the U.K. analysis of 80 cases from a 20-year birth cohort. Br J Haematol 1992; 94: 645-653.
69. Diamond LK, Wang WC, Alter BP. Congenital hypoplastic anemia. Adv Pediatr 1976; 22: 349-378.
70. Ozawa K, Kurtzman G, Young N. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood 1987; 70: 384-391.
71. Morey AL, Ferguson DJ, Fleming KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: evidence of cell death by apoptosis. J Pathol 1993; 169: 213-220.
72. Takahashi T, Ozawa K, Takahashi K, et al. Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 1990; 75: 603-610.
73. Koduri PR. Novel cytomorphology of the giant proerythroblasts of parvovirus B19 infection. Am J Hematol 1998; 58: 95-99.
74. Morey AL, Keeling JW, Porter HJ, et al. Clinical and histopathological features of parvovirus B19 infection in human fetus. Br J Obstet Gynaecol 1992; 99: 566-574.
75. Mitsuyasu RT, Lambertus M, Goetz MB. Transfusion-dependent anemia in a patient with AIDS (Infectious Disease Rounds). Clin Infect Dis 1992; 15: 533-539.
76. Caper E, Kurtman GJ. Human parvovirus B19 infection. Curr Opin Hematol 1996; 3: 111-117.
77. Owren PA. Congenital hemolytic jaundice. The pathogenesis of the 'hemolytic crisis'. Blood 1998; 3: 231-248.
78. Harris JW. Parvovirus B19 for the hematologist. Am J Hematol 1992; 39: 119-130.
79. Sadahira Y, Sugihara T, Yawata Y. Expression of p53 and Ki-67 antigen in bone marrow giant proerythroblasts associated with human parvovirus B19 infection. Int J Hematol 2001; 74: 147-152.
80. Pallier C, Greco A, Le Junter J, et al. The 3′ untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in non-permissive cells. J Virol 1997; 71: 9482-9489.
81. Caillet-Fauquet P, Perros M, et al. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO J 1990; 9: 2989-2995.
82. Sol N, Le Junter J, Vassias I, et al. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol 1999; 73: 8762-8770.
83. Lindton B, Tolfvenstam T, Norbeck O, et al. Recombinant parvovirus B19 empty capsids inhibit fetal hematopoietic colony formation in vitro. Fetal Diagn Ther 2001; 16: 26-31.
84. Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001 412: 914-917.
85. Fortunato EA, Spector DH. Viral induction of site-specific chromosome damage. Rev Med Virol 2003; 13: 21-37.
86. De Beeck AO, Sobczak-Thepot J, Sirma H, et al. NS1-and minute virus of mice-induced cell cycle arrest: involvement of p53 and p21 (cip1). J Virol 2001; 75: 11071-11078.
87. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
88. Numa F, Hirabayashi K, Tsunaga N, et al. Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293T cells. Cancer Res 1995; 55: 4676-4680.